Author:
Imazu Miki,Fukuda Hiroki,Kanzaki Hideaki,Amaki Makoto,Hasegawa Takuya,Takahama Hiroyuki,Hitsumoto Tatsuro,Tsukamoto Osamu,Morita Toshisuke,Ito Shin,Kitakaze Masafumi
Abstract
AbstractIndoxyl sulfate (IS) is associated with either chronic kidney disease or renal failure, which may predict cardiovascular events via cardiorenal syndrome. The present study aimed to elucidate whether the plasma levels of IS can predict the occurrence of cardiovascular events in patients with chronic heart failure (CHF) and investigate which causes of CHF leading to cardiovascular events are highly influenced by plasma IS levels. We measured the plasma IS levels in 165 patients with CHF [valvular disease: 78, dilated cardiomyopathy: 29, hypertrophic cardiomyopathy (HCM): 25 and others: 33] admitted to our hospital in 2012, and we followed up these patients for more than 5 years (the median follow-up period: 5.3 years). We measured the plasma IS level in 165 patients with CHF, and Kaplan–Meier analyses showed that high plasma IS levels (≥ 0.79 µg/mL, the median value) could predict the occurrence of cardiovascular events, i.e., cardiovascular death or rehospitalization due to the worsening of CHF. The sub-analyses showed that the high IS level could predict cardiovascular events in patients with CHF due to HCM and that the plasma IS levels were closely associated with left ventricular (LV) dimension, LV systolic dysfunction, and plasma B-type natriuretic peptide levels, rather than LV diastolic dysfunction. Plasma IS level predicts cardiovascular events in patients with CHF, especially those with HCM along with cardiac dysfunction. Besides, IS may become a proper biomarker to predict cardiovascular events in patients with CHF.
Funder
the Ministry of Health, Labor, and Welfare-Japan
the Ministry of Education, Culture, Sports, Science and Technology-Japan
Japan Agency for Medical Research and Development, AMED
the Japan Heart Foundation and Grants from the Japan Cardiovascular Research Foundation
the collaborative research with Kureha Corporation and Mitsubishi Tanabe Pharma Corporation
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Silverberg, D. S., Wexler, D., Blum, M. & Iaina, A. The cardio renal anemia syndrome: Correcting anemia in patients with resistant congestive heart failure can improve both cardiac and renal function and reduce hospitalizations. Clin. Nephrol. 60(Suppl 1), S93-102 (2003).
2. Lekawanvijit, S., Kompa, A. R., Wang, B. H., Kelly, D. J. & Krum, H. Cardiorenal syndrome: The emerging role of protein-bound uremic toxins. Circ. Res. 111, 1470–1483. https://doi.org/10.1161/circresaha.112.278457 (2012).
3. Duranton, F. et al. Normal and pathologic concentrations of uremic toxins. J. Am. Soc. Nephrol. JASN 23, 1258–1270. https://doi.org/10.1681/asn.2011121175 (2012).
4. Lin, C.-J., Wu, V., Wu, P.-C. & Wu, C.-J. Meta-analysis of the associations of p-cresyl sulfate (PCS) and indoxyl sulfate (IS) with cardiovascular events and all-cause mortality in patients with chronic renal failure. PLoS ONE 10, e0132589 (2015).
5. Niwa, T. et al. Indoxyl sulfate and progression of renal failure: Effects of a low-protein diet and oral sorbent on indoxyl sulfate production in uremic rats and undialyzed uremic patients. Miner. Electrolyte Metab. 23, 179–184 (1997).
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献